BACKGROUND AND PURPOSE: Childhood white matter disorders often show similar MR imaging signal-intensity changes, despite different underlying pathophysiologies. The purpose of this study was to determine if proton MR spectroscopic imaging ((1)H-MRSI) may help identify tissue pathophysiology in patients with leukoencephalopathies. MATERIALS AND METHODS: Seventy patients (mean age, 6; range, 0.66-17 years) were prospectively examined by (1)H-MRSI; a diagnosis of leukoencephalopathy due to known genetic defects leading to lack of formation, breakdown of myelin, or loss of white matter tissue attenuation (rarefaction) was made in 47 patients. The diagnosis remained undefined (UL) in 23 patients. Patients with definite diagnoses were assigned (on the basis of known pathophysiology) to 3 groups corresponding to hypomyelination, white matter rarefaction, and demyelination. Choline (Cho), creatine (Cr), and N-acetylaspartate (NAA) signals from 6 white matter regions and their intra- and intervoxel (relative to gray matter) ratios were measured. Analysis of variance was performed by diagnosis and by pathophysiology group. Stepwise linear discriminant analysis was performed to construct a model to predict pathophysiology on the basis of (1)H-MRSI, and was applied to the UL group. RESULTS: Analysis of variance by diagnosis showed 3 main metabolic patterns. Analysis of variance by pathophysiology showed significant differences for Cho/NAA (P < .001), Cho/Cr (P < .004), and NAA/Cr (P < .002). Accuracy of the linear discriminant analysis model was 75%, with Cho/Cr and NAA/Cr being the best parameters for classification. On the basis of the linear discriminant analysis model, 61% of the subjects in the UL group were classified as hypomyelinating. CONCLUSION: (1)H-MRSI provides information on tissue pathophysiology and may, therefore, be a valuable tool in the evaluation of patients with leukoencephalopathies.
BACKGROUND AND PURPOSE: Childhood white matter disorders often show similar MR imaging signal-intensity changes, despite different underlying pathophysiologies. The purpose of this study was to determine if proton MR spectroscopic imaging ((1)H-MRSI) may help identify tissue pathophysiology in patients with leukoencephalopathies. MATERIALS AND METHODS: Seventy patients (mean age, 6; range, 0.66-17 years) were prospectively examined by (1)H-MRSI; a diagnosis of leukoencephalopathy due to known genetic defects leading to lack of formation, breakdown of myelin, or loss of white matter tissue attenuation (rarefaction) was made in 47 patients. The diagnosis remained undefined (UL) in 23 patients. Patients with definite diagnoses were assigned (on the basis of known pathophysiology) to 3 groups corresponding to hypomyelination, white matter rarefaction, and demyelination. Choline (Cho), creatine (Cr), and N-acetylaspartate (NAA) signals from 6 white matter regions and their intra- and intervoxel (relative to gray matter) ratios were measured. Analysis of variance was performed by diagnosis and by pathophysiology group. Stepwise linear discriminant analysis was performed to construct a model to predict pathophysiology on the basis of (1)H-MRSI, and was applied to the UL group. RESULTS: Analysis of variance by diagnosis showed 3 main metabolic patterns. Analysis of variance by pathophysiology showed significant differences for Cho/NAA (P < .001), Cho/Cr (P < .004), and NAA/Cr (P < .002). Accuracy of the linear discriminant analysis model was 75%, with Cho/Cr and NAA/Cr being the best parameters for classification. On the basis of the linear discriminant analysis model, 61% of the subjects in the UL group were classified as hypomyelinating. CONCLUSION: (1)H-MRSI provides information on tissue pathophysiology and may, therefore, be a valuable tool in the evaluation of patients with leukoencephalopathies.
Authors: J Patrick van der Voorn; Petra J W Pouwels; Augustinus A M Hart; Judith Serrarens; Michèl A A P Willemsen; Hubertus P H Kremer; Frederik Barkhof; Marjo S van der Knaap Journal: Radiology Date: 2006-11 Impact factor: 11.105
Authors: Florian S Eichler; Ryuta Itoh; Peter B Barker; Susumu Mori; Elizabeth S Garrett; Peter C M van Zijl; Hugo W Moser; Gerald V Raymond; Elias R Melhem Journal: Radiology Date: 2002-10 Impact factor: 11.105
Authors: J P van der Voorn; P J W Pouwels; J M Powers; W Kamphorst; J-J Martin; D Troost; M D Spreeuwenberg; F Barkhof; M S van der Knaap Journal: AJNR Am J Neuroradiol Date: 2011-01-27 Impact factor: 3.825
Authors: M Koob; V Laugel; M Durand; H Fothergill; C Dalloz; F Sauvanaud; H Dollfus; I J Namer; J-L Dietemann Journal: AJNR Am J Neuroradiol Date: 2010-06-03 Impact factor: 3.825
Authors: Maria Zulfiqar; Doris D M Lin; Marinette Van der Graaf; Peter B Barker; Jill A Fahrner; Sandrine Marie; Eva Morava; Lonneke De Boer; Michel A A P Willemsen; Eileen Vining; Alena Horská; Udo Engelke; Ron A Wevers; Gustavo H B Maegawa Journal: J Magn Reson Imaging Date: 2012-10-10 Impact factor: 4.813
Authors: Elisabetta Flex; Marcello Niceta; Serena Cecchetti; Isabelle Thiffault; Margaret G Au; Alessandro Capuano; Emanuela Piermarini; Anna A Ivanova; Joshua W Francis; Giovanni Chillemi; Balasubramanian Chandramouli; Giovanna Carpentieri; Charlotte A Haaxma; Andrea Ciolfi; Simone Pizzi; Ganka V Douglas; Kara Levine; Antonella Sferra; Maria Lisa Dentici; Rolph R Pfundt; Jean-Baptiste Le Pichon; Emily Farrow; Frank Baas; Fiorella Piemonte; Bruno Dallapiccola; John M Graham; Carol J Saunders; Enrico Bertini; Richard A Kahn; David A Koolen; Marco Tartaglia Journal: Am J Hum Genet Date: 2016-09-22 Impact factor: 11.025
Authors: Jennifer L Orthmann-Murphy; Ettore Salsano; Charles K Abrams; Alberto Bizzi; Graziella Uziel; Mona M Freidin; Eleonora Lamantea; Massimo Zeviani; Steven S Scherer; Davide Pareyson Journal: Brain Date: 2008-12-04 Impact factor: 13.501